(-0.50%) 4 986.26 points
(0.62%) 38 009 points
(-1.43%) 15 378 points
(1.08%) $83.62
(-0.17%) $1.754
(0.65%) $2 413.60
(1.46%) $28.80
(-1.11%) $943.90
(-0.07%) $0.939
(-0.23%) $11.02
(0.49%) $0.808
(-0.94%) $93.02
Live Chart Being Loaded With Signals
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions...
Stats | |
---|---|
Today's Volume | 160 600 |
Average Volume | 167 880 |
Market Cap | 7.54B |
EPS | ¥0 ( 2024-02-08 ) |
Next earnings date | ( ¥0 ) 2024-05-10 |
Last Dividend | ¥0 ( N/A ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -6.41 |
ATR14 | ¥1.099 (0.25%) |
Volume Correlation
Carna Biosciences, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Carna Biosciences, Inc. Correlation - Currency/Commodity
Carna Biosciences, Inc. Financials
Annual | 2023 |
Revenue: | ¥1.63B |
Gross Profit: | ¥1.45B (89.22 %) |
EPS: | ¥-68.62 |
Q4 | 2023 |
Revenue: | ¥914.60M |
Gross Profit: | ¥862.95M (94.35 %) |
EPS: | ¥4.52 |
Q3 | 2023 |
Revenue: | ¥210.72M |
Gross Profit: | ¥169.76M (80.56 %) |
EPS: | ¥-20.13 |
Q2 | 2023 |
Revenue: | ¥273.60M |
Gross Profit: | ¥239.55M (87.56 %) |
EPS: | ¥-21.46 |
Financial Reports:
No articles found.
Carna Biosciences, Inc.
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection and interaction, live-cell kinase assay, ClariCELL kinase cell-based assay, crystallization, weak affinity chromatography, and tyrosine kinase cell-based assay services, as well as custom production of ultra-pure proteins for crystallography. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials. The company has collaborations with Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals. Carna Biosciences, Inc. was founded in 2003 and is based in Kobe, Japan.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators